Hanhan Shi, Yunhan Zhu, Jie Yang, Mingpeng Xu, Lu Chen, Yanping Han, Min Zhou, Minglei Han, Jia Tan, Renbing Jia, Peiwei Chai, Xuyang Wen, Jiayan Fan
{"title":"Lack of long-term benefit from anti-VEGF combined therapy in cT2b retinoblastoma.","authors":"Hanhan Shi, Yunhan Zhu, Jie Yang, Mingpeng Xu, Lu Chen, Yanping Han, Min Zhou, Minglei Han, Jia Tan, Renbing Jia, Peiwei Chai, Xuyang Wen, Jiayan Fan","doi":"10.1016/j.oret.2025.10.007","DOIUrl":null,"url":null,"abstract":"<p><p>This prospective clinical trial showed that vincristine-etoposide-carboplatin (VEC) plus intravitreal anti-VEGF therapy offers limited long-term benefits for patients with unilateral advanced retinoblastoma.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oret.2025.10.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This prospective clinical trial showed that vincristine-etoposide-carboplatin (VEC) plus intravitreal anti-VEGF therapy offers limited long-term benefits for patients with unilateral advanced retinoblastoma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
